The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals

Abstract

Objectives: A decrease in blood cell counts, especially lymphocytes and eosinophils, has been described in patients with serious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), but there is no knowledge of their potential role of the recovery in these patients’ prognosis. This article aims to analyse the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Design: This work was a retrospective, multicentre cohort study of 9644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine’s SEMI-COVID-19 Registry. Setting: This study examined patients hospitalised in 147 hospitals throughout Spain. Participants: This work analysed 9644 patients (57.12% male) out of a cohort of 12,826 patients ≥18 years of age hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020. Main outcome measures: The main outcome measure of this work is the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death, and then multivariate analysis was carried out to control for potential confounders. Results: An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs. 22.6% in non-recoverers, OR 0.234; 95% CI, 0.154 to 0.354) and lower complication rates, especially regarding the development of acute respiratory distress syndrome (8% vs. 20.1%, p = 0.000) and ICU admission (5.4% vs. 10.8%, p = 0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor. Conclusion: Eosinophil recovery in patients with COVID-19 who required hospitalisation had an independent prognostic value for all-cause mortality and a milder course.

Eosinophil: A Nonnegligible Predictor in COVID-19 Re-Positive Patients

“…Consistently, the ICU metastasis rate was significantly higher in the eosinopenia group than in the non-eosinopenia group ( 31 ). Moreover, eosinophil reduction has been reported in patients with SARS-CoV-2 infection, which can be improved when the viral load in patients is reduced ( 27 , 32 ), and a study have shown that the recovery of eosinophils has independent prognostic value for the course of mild diseases ( 33 ). One study tested the hypothesis that the decrease in eosinophils was associated with a malfunction of the innate immune response, and found that the decrease in eosinophils was specific for COVID-19 ( 34 ).…”

Cell Population Data and Serum Polyclonal Immunoglobulin Free Light Chains in the Assessment of COVID-19 Severity

“…A relationship was demonstrated between the number of eosinophils and the mortality rate. Scientists have shown that an increase in the number of peripheral blood eosinophils has a positive effect on prognosis and lowers the mortality rate (OR) [ 17 ]. Mao et al, in their study, assessed the effect of the number of eosinophils on the severity of the disease.…”

Association between the peripheral blood eosinophil counts and COVID-19

“…[ 39 ] In surviving acute lung injury patients, the number of eosinophils in the lungs showed an increased compared to the non-survivors. [ 40 ] Similarly, the number of peripheral blood eosinophils also increased in surviving acute respiratory distress syndrome patients. Therefore, the scholars further investigated its molecular mechanism and found that in the initiation of acute lung injury, CD101 − eosinophils increased more rapidly and briefly than the neutrophils and secreted Protectin-D1 through Alox15-mediated to reduce the accumulation of inflammatory cells and reduce inflammatory factors, thus playing a role in fighting lung inflammation.…”